{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:26:03Z","timestamp":1781166363191,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda (China) International Trading Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Relapsed or refractory classic Hodgkin lymphoma (RRcHL) associates with poor prognosis and heavy disease burden to patients. This study evaluated the cost-effectiveness of brentuximab vedotin (BV) in comparison to conventional chemotherapy in patients with RRcHL, from a Chinese healthcare perspective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The lifetime cost and quality adjusted life years (QALYs) were estimated through a partitioned survival model with three health states (progression free, post progression, and death). Two cohorts for each BV arm and chemotherapy arm were built, representing patients with and without transplant after BV or chemotherapy, respectively. Clinical parameters were retrieved from BV trials and the literature. Resource utilization data were mainly collected from local expert surveys and cost parameters were reflecting local unit prices. Utility values were sourced from the literature. A discount rate of 5% was employed according to the Chinese guideline. A series of deterministic and probabilistic sensitivity analyses were conducted to evaluate the robustness and uncertainty associated with the model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Results of the base case analysis showed that the incremental cost-effectiveness ratio (ICER) for BV versus chemotherapy was $2,867 (\u00a519,774). The main model driver was the superior progression-free and overall survival benefits of BV. The ICERs were relatively robust in a series of sensitivity analyses, all under a conventional decision threshold (1 time of Chinese per capita GDP). With this conventional threshold, the probability of BV being cost-effective was 100%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Brentuximab vedotin can be considered a cost-effective treatment versus conventional chemotherapy in treating relapsed or refractory classic Hodgkin lymphoma in China.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13561-024-00514-6","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T10:03:48Z","timestamp":1717668228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China"],"prefix":"10.1186","volume":"14","author":[{"given":"Shitong","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Hsiang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"514_CR1","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines Version 2. 2022 Hodgkin Lymphoma. Published online 2022. https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/4\/article-p322.xml?ArticleBodyColorStyles=inline%20pdf. Accessed January 15, 2023."},{"key":"514_CR2","unstructured":"World Health Organization. Globancan 2020. Published online 2021. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/900-world-fact-sheets.pdf. Accessed December 14, 2022."},{"key":"514_CR3","unstructured":"World Health Organization. Globancan 2020, China. Published online 2021. http:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/160-china-fact-sheets.pdf. Accessed December 14, 2022."},{"key":"514_CR4","unstructured":"China Cancer Registry Annual Report. Published online 2017. http:\/\/www.phirda.com\/artilce_27200.html?cId=1. Accessed December 14, 2022."},{"key":"514_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378:331\u201344.","journal-title":"N Engl J Med"},{"key":"514_CR6","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","volume":"54","author":"S Arai","year":"2013","unstructured":"Arai S, Fanale M, deVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54:2531\u20133.","journal-title":"Leuk Lymphoma"},{"key":"514_CR7","first-page":"abstract118","volume":"19","author":"S Horning","year":"2008","unstructured":"Horning S, Fanale M, deVos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. Ann Oncol. 2008;19:abstract118.","journal-title":"Ann Oncol"},{"key":"514_CR8","first-page":"60","volume":"(1)","author":"F Wang","year":"2020","unstructured":"Wang F, Tao L, Dong D, et al. A survey of disease burden of Hodgkin\u2019s lymphoma patients in China\u2014\u2014based on an online questionnaire research. China Health Insurance. 2020;(1):60\u20134.","journal-title":"China Health Insurance"},{"issue":"11","key":"514_CR9","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.3109\/10428194.2015.1030639","volume":"56","author":"C Yasenchak","year":"2015","unstructured":"Yasenchak C, Tseng W, Yap M, et al. Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma. Leuk Lymphoma. 2015;56(11):3143\u20139.","journal-title":"Leuk Lymphoma"},{"key":"514_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2147\/CEOR.S178649","volume":"10","author":"M Bonafede","year":"2018","unstructured":"Bonafede M, Feliciano J, Cai Q, et al. Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure. Clinicoecon Outcomes Res. 2018;10:629\u201341.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"7","key":"514_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nbt.2289","volume":"10","author":"P Senter","year":"2012","unstructured":"Senter P, Sievers E. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;10(7):631\u20137.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"514_CR12","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"J Francisco","year":"2003","unstructured":"Francisco J, Cerveny C, Meyer D, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458\u201365.","journal-title":"Blood"},{"key":"514_CR13","unstructured":"Food and Drug Administration. ADCETRISVR(brentuximab vedotin) for Injection. Full prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125388s106lbl.pdf. Accessed December 14, 2022."},{"key":"514_CR14","unstructured":"European Medicines Agency. ADCETRISVR 50\u00a0mg powder for concentrate forsolution for infusion. Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adcetris-epar-product-information_en.pdf. Accessed December 14, 2022."},{"key":"514_CR15","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal A, Smith S. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"514_CR16","first-page":"2736","volume":"126","author":"R Chen","year":"2015","unstructured":"Chen R, Gopal A, Smith S, et al. Five-year survival data demonstrating durable responses from a pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood Transfus. 2015;126:2736.","journal-title":"Blood Transfus"},{"key":"514_CR17","unstructured":"China. approval 2020. https:\/\/www.takeda.com\/newsroom\/newsreleases\/2020\/takeda-china-announces-adcetris-brentuximab-vedotin-is-approved-for-the-treatment-of-adult-patients-with-cd30-positive-lymphomas\/. Accessed December 14, 2022."},{"key":"514_CR18","volume-title":"Lymphoid malignancies guideline","author":"The Chinese Society of Clinical Oncology (CSCO)","year":"2022","unstructured":"The Chinese Society of Clinical Oncology (CSCO). Lymphoid malignancies guideline. Beijing: People health; 2022."},{"key":"514_CR19","unstructured":"Takeda China. Adced label instruction. https:\/\/assets-dam.takeda.com\/raw\/upload\/v1675870089\/legacy-dotcom\/siteassets\/zh-cn\/home\/what-we-do\/our-products\/__20210413.pdf. Accessed December 14, 2022."},{"key":"514_CR20","unstructured":"Lui GG. China Guidelines for Pharmacoeconomic Evaluation. Published online. 2020. https:\/\/www.cpa.org.cn\/cpadmn\/attached\/file\/20201203\/1606977380634185.pdf. Accessed December 20, 2022."},{"issue":"1","key":"514_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/13696998.2016.1219358","volume":"20","author":"C Parker","year":"2017","unstructured":"Parker C, Woods B, Eaton J, et al. Brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. J Med Econ. 2017;20(1):8\u201318.","journal-title":"J Med Econ"},{"issue":"9","key":"514_CR22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/17474086.2021.1942831","volume":"14","author":"Y Song","year":"2021","unstructured":"Song Y, Guo Y, Huang H, et al. Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed\/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Expert Rev Hematol. 2021;14(9):867\u201375.","journal-title":"Expert Rev Hematol"},{"key":"514_CR23","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1093\/annonc\/mdt206","volume":"24","author":"C Martinez","year":"2013","unstructured":"Martinez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin\u2019s lymphoma patient relapsing after autologous stem cell transplantation. Ann Oncol. 2013;24:2430\u20134.","journal-title":"Ann Oncol"},{"key":"514_CR24","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","volume":"28","author":"P Brockelmann","year":"2017","unstructured":"Brockelmann P, Muller H, Casasnovas O, et al. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2017;28:1352\u20138.","journal-title":"Ann Oncol"},{"key":"514_CR25","unstructured":"Beijing Social Security Network. Beiging healthcare service reimbursement standard. Published online 2017. https:\/\/m.chashebao.com\/beijing\/yiliao\/17287.html. Accessed December 14, 2022."},{"key":"514_CR26","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-related Infections. Published online 2016. https:\/\/jnccn.org\/view\/journals\/jnccn\/14\/7\/article-p882.xml?ArticleBodyColorStyles=Inline%20PDF. Accessed December 14, 2022."},{"key":"514_CR27","unstructured":"Natioanl Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Published online 2016. https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed December 14, 2022."},{"key":"514_CR28","unstructured":"Yaozh website. https:\/\/www.yaozh.com\/. Accessed December 14, 2022."},{"issue":"6","key":"514_CR29","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3109\/10428194.2014.970542","volume":"56","author":"P Swinburn","year":"2015","unstructured":"Swinburn P, Shingler S, Acaster S, et al. Health utilities in relation to treatment response and adverse events in relapsed\/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2015;56(6):1839\u201345.","journal-title":"Leuk Lymphoma"},{"key":"514_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/oxfordjournals.annonc.a010542","volume":"1","author":"P Bierman","year":"1996","unstructured":"Bierman P, Anderson J, Freeman M, et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin\u2019s disease patients following first relapse after chemotherapy. Ann Oncol. 1996;1:151\u20136.","journal-title":"Ann Oncol"},{"key":"514_CR31","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.3747\/co.24.3369","volume":"24","author":"V Babashov","year":"2017","unstructured":"Babashov V, Begen MA, Mangel J, et al. Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma. Curr Oncol. 2017;24:e6\u201314.","journal-title":"Curr Oncol"},{"issue":"7","key":"514_CR32","doi-asserted-by":"publisher","first-page":"A637","DOI":"10.1016\/j.jval.2014.08.2290","volume":"17","author":"B Meza-Torres","year":"2014","unstructured":"Meza-Torres B, Gay JG, Jakouloff DE. Cost-effectiveness evaluation of brentuximab vedotin for refractory\/relapsed Hodgkin lymphoma: a comparative analysis of the results of Mexico and Venezuela. Value Health. 2014;17(7):A637.","journal-title":"Value Health"},{"issue":"7","key":"514_CR33","doi-asserted-by":"publisher","first-page":"A639","DOI":"10.1016\/j.jval.2014.08.2303","volume":"17","author":"A Engstrom","year":"2014","unstructured":"Engstrom A. The cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma in Sweden. Value Health. 2014;17(7):A639.","journal-title":"Value Health"},{"key":"514_CR34","doi-asserted-by":"publisher","first-page":"S650","DOI":"10.1016\/j.annonc.2020.08.006","volume":"31","author":"B Von Tresckow","year":"2020","unstructured":"Von Tresckow B, Bergamasco A, Trinchese F, Gavini F, et al. 888MO effectiveness of brentuximab vedotin in relapsed\/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol. 2020;31:S650.","journal-title":"Ann Oncol"},{"issue":"1","key":"514_CR35","first-page":"10","volume":"9","author":"M Ramzi","year":"2015","unstructured":"Ramzi M, Rezvani A, Dehghani M. GDP versus ESHAP Regimen in Relapsed and\/or refractory Hodgkin lymphoma: a comparison study. Int J Hematol Oncol Stem Cell Res. 2015;9(1):10\u20134.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"6","key":"514_CR36","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","volume":"18","author":"N Bartlett","year":"2007","unstructured":"Bartlett N, Niedzwiecki D, Johnson J, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"514_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.10661","volume":"92","author":"A Santoro","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica. 2007;92(1):35\u201341.","journal-title":"Haematologica"},{"issue":"11","key":"514_CR38","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3109\/10428190903254383","volume":"50","author":"E Cavalieri","year":"2009","unstructured":"Cavalieri E, Matturro A, Annechini G, et al. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma. 2009;50(11):1803\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"514_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","volume":"71","author":"WS Velasquez","year":"1988","unstructured":"Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71(1):117\u201322.","journal-title":"Blood"},{"key":"514_CR40","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","volume":"327","author":"GP Canellos","year":"1992","unstructured":"Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478\u201384.","journal-title":"N Engl J Med"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-024-00514-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-024-00514-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-024-00514-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T10:11:10Z","timestamp":1717668670000},"score":1,"resource":{"primary":{"URL":"https:\/\/healtheconomicsreview.biomedcentral.com\/articles\/10.1186\/s13561-024-00514-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["514"],"URL":"https:\/\/doi.org\/10.1186\/s13561-024-00514-6","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"assertion":[{"value":"6 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Yanan Sheng is employee of Takeda (China) International Trading Company. The other authors have no competing Interest declaration to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}